Published in Drug Metab Dispos on July 01, 2001
Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain. Proc Natl Acad Sci U S A (2008) 1.40
Allosteric P450 mechanisms: multiple binding sites, multiple conformers or both? Expert Opin Drug Metab Toxicol (2008) 1.31
Resolution of multiple substrate binding sites in cytochrome P450 3A4: the stoichiometry of the enzyme-substrate complexes probed by FRET and Job's titration. Biochemistry (2006) 1.21
Cooperative properties of cytochromes P450. Pharmacol Ther (2009) 1.09
Substrate binding to cytochromes P450. Anal Bioanal Chem (2008) 1.09
CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Mol Pharmacol (2005) 1.08
An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol (2006) 1.00
Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites. Drug Metab Dispos (2009) 0.98
Cholesterol-metabolizing cytochromes P450: implications for cholesterol lowering. Expert Opin Drug Metab Toxicol (2008) 0.94
Kinetics of electron transfer in the complex of cytochrome P450 3A4 with the flavin domain of cytochrome P450BM-3 as evidence of functional heterogeneity of the heme protein. Arch Biochem Biophys (2007) 0.90
Role of subunit interactions in P450 oligomers in the loss of homotropic cooperativity in the cytochrome P450 3A4 mutant L211F/D214E/F304W. Arch Biochem Biophys (2007) 0.89
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors. Drug Metab Dispos (2010) 0.88
A pharmacogenetic study of vorinostat glucuronidation. Pharmacogenet Genomics (2010) 0.86
Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions. Drug Metab Dispos (2013) 0.82
Inhibition of recombinant cytochrome P450 isoforms 2D6 and 2C9 by diverse drug-like molecules. J Med Chem (2007) 0.79
Indole peroxygenase activity of indoleamine 2,3-dioxygenase. Proc Natl Acad Sci U S A (2012) 0.78
Effects of some commonly used Saudi folk herbal medications on the metabolic activity of CYP2C9 in human liver microsomes. Saudi Pharm J (2010) 0.77
Functioning of drug-metabolizing microsomal cytochrome P450s: In silico probing of proteins suggests that the distal heme 'active site' pocket plays a relatively 'passive role' in some enzyme-substrate interactions. In Silico Pharmacol (2016) 0.76
Regulation of very-long acyl chain ceramide synthesis by Acyl-CoA binding protein. J Biol Chem (2017) 0.75
Effective virtual screening protocol for CYP2C9 ligands using a screening site constructed from flurbiprofen and S-warfarin pockets. J Comput Aided Mol Des (2007) 0.75
Cytochrome P450: new nomenclature and clinical implications. Am Fam Physician (1998) 2.56
Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry (1998) 1.93
Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metab Dispos (2001) 1.42
Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. Am J Physiol (1999) 1.18
Indices of activity of the nitric oxide system in hemodialysis patients. Am J Kidney Dis (1999) 1.14
Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity. Br J Clin Pharmacol (2006) 0.92
Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. Eur J Pharm Sci (2001) 0.88
Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes. Drug Metab Dispos (2000) 0.85
Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A. Drug Metab Dispos (1998) 0.85
The effectiveness of prophylactic etodolac on postendodontic pain. J Endod (2000) 0.84
Comparative modelling of the human UDP-glucuronosyltransferases: insights into structure and mechanism. Xenobiotica (2007) 0.82
Rapid and sensitive high-performance liquid chromatographic assay for 6-hydroxychlorzoxazone and chlorzoxazone in liver microsomes. J Chromatogr B Biomed Sci Appl (1997) 0.82
Effects of gestational and overt diabetes on human placental cytochromes P450 and glutathione S-transferase. Drug Metab Dispos (1998) 0.82
Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos (1999) 0.82
In vitro reaction of barbiturates with formaldehyde. J Anal Toxicol (2001) 0.81
Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6. Drug Metab Dispos (2001) 0.80
Effect of its deaminated metabolite, 2',2'-difluorodeoxyuridine, on the transport and toxicity of gemcitabine in HeLa cells. Biochem Pharmacol (2011) 0.80
Single dose pharmacokinetics of syrup of ipecac. Ther Drug Monit (2000) 0.79
Sensitive and specific high-performance liquid chromatographic assay for 4'-hydroxyflurbiprofen and flurbiprofen in human urine and plasma. J Chromatogr B Biomed Sci Appl (2000) 0.79
Effect of protein-calorie malnutrition on cytochromes P450 and glutathione S-transferase. Eur J Drug Metab Pharmacokinet (1999) 0.78
Metabolism of a bisphosphonate ester (PNU-91638) in rat. Xenobiotica (1997) 0.77
Metabolism of the bisphosphonate ester U-91502 in rats. Drug Metab Dispos (1996) 0.77
In vitro reaction of formaldehyde with fenfluramine: conversion to N-methyl fenfluramine. J Anal Toxicol (2001) 0.76
Comment: delirium probably induced by clarithromycin in a patient receiving fluoxetine. Ann Pharmacother (1996) 0.75
Identification of the metabolites of the HIV-1 reverse transcriptase inhibitor delavirdine in monkeys. Drug Metab Dispos (1997) 0.75
Regiospecificity of placental metabolism by cytochromes P450 and glutathione S-transferase. Gynecol Obstet Invest (1996) 0.75
Stability of high-dose vancomycin and ceftazidime in peritoneal dialysis solutions. Am J Health Syst Pharm (1999) 0.75
Metabolism of the HIV-1 reverse transcriptase inhibitor delavirdine in mice. Drug Metab Dispos (1997) 0.75
Human biotransformation of bropirimine. Characterization of the major bropirimine oxidative metabolites formed in vitro. Drug Metab Dispos (1998) 0.75
Biotransformation of tirilazad in human: 3. tirilazad A-ring reduction by human liver microsomal 5alpha-reductase type 1 and type 2. J Pharmacol Exp Ther (1998) 0.75
Calcium modulators: future agents, future uses. Drug Intell Clin Pharm (1987) 0.75
Quantitative analysis quantitation of 2-n-nonyl-1,3-dioxolane by stable-isotope dilution gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl (1998) 0.75
Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats. Drug Metab Dispos (1997) 0.75
The effects of diabetes on placental aromatase activity. J Steroid Biochem Mol Biol (1998) 0.75
In vitro and in vivo biotransformation of 6,7-dimethyl-2,4-di-1-pyrrolidinyl-7H-pyrrolo[2,3-D]pyrimidine (U-89843) in the rat. Drug Metab Dispos (1996) 0.75
Bioactivation of 6,7-dimethyl-2,4-di-1-pyrrolidinyl-7H-pyrrolo[2,3-d]pyrimidine (U-89843) to reactive intermediates that bind covalently to macromolecules and produce genotoxicity. Chem Res Toxicol (1996) 0.75